<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39204327</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">982</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16080982</ELocationID><Abstract><AbstractText>Multitarget compounds have emerged as promising drug candidates to cope with complex multifactorial diseases, like Alzheimer's disease (AD). Most multitarget compounds are designed by linking two pharmacophores through a tether chain (linked hybrids), which results in rather large molecules that are particularly useful to hit targets with large binding cavities, but at the expense of suffering from suboptimal physicochemical/pharmacokinetic properties. Molecular size reduction by removal of superfluous structural elements while retaining the key pharmacophoric motifs may represent a compromise solution to achieve both multitargeting and favorable physicochemical/PK properties. Here, we report the stepwise structural simplification of the dihydroxyanthraquinone moiety of a rhein-huprine hybrid lead by hydroxy group removal-ring contraction-ring opening-ring removal, which has led to new analogs that retain or surpass the potency of the lead on its multiple AD targets while exhibiting more favorable drug metabolism and pharmacokinetic (DMPK) properties and safety profile. In particular, the most simplified acetophenone analog displays dual nanomolar inhibition of human acetylcholinesterase and butyrylcholinesterase (IC<sub>50</sub> = 6 nM and 13 nM, respectively), moderately potent inhibition of human BACE-1 (48% inhibition at 15 µM) and Aβ42 and tau aggregation (73% and 68% inhibition, respectively, at 10 µM), favorable in vitro brain permeation, higher aqueous solubility (18 µM) and plasma stability (100/96/86% remaining in human/mouse/rat plasma after 6 h incubation), and lower acute toxicity in a model organism (zebrafish embryos; LC<sub>50</sub> &gt;&gt; 100 µM) than the initial lead, thereby confirming the successful lead optimization by structural simplification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pont</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampietro</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1837-2051</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine of the University of Barcelona (IBUB), E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Areales</LastName><ForeName>F Javier</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0001-9525-9346</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine of the University of Barcelona (IBUB), E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristiano</LastName><ForeName>Nunzia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albalat</LastName><ForeName>Agustí</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Belén</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5801-1704</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, E-08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolini</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2890-3856</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro, 6, I-40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Simone</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1915-458X</Identifier><AffiliationInfo><Affiliation>Department of Drug Science and Technology, University of Turin, I-10125 Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrisano</LastName><ForeName>Vincenza</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-4396-1904</Identifier><AffiliationInfo><Affiliation>Department for Life Quality Studies, Alma Mater Studiorum University of Bologna, Corso d'Augusto 237, I-47921 Rimini, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barenys</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for the Protection of Laboratory Animals (Bf3R), German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixidó</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0146-876X</Identifier><AffiliationInfo><Affiliation>Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nutrition and Food Safety of the University of Barcelona (INSA-UB), E-08921 Santa Coloma de Gramenet, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabaté</LastName><ForeName>Raimon</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3894-2362</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy and Pharmaceutical Technology and Physical-Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loza</LastName><ForeName>M Isabel</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Universidade de Santiago de Compostela, Av. de Barcelona s/n, E-15782 Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brea</LastName><ForeName>José</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5523-1979</Identifier><AffiliationInfo><Affiliation>BioFarma Research Group, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, Universidade de Santiago de Compostela, Av. de Barcelona s/n, E-15782 Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muñoz-Torrero</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8140-8555</Identifier><AffiliationInfo><Affiliation>Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine of the University of Barcelona (IBUB), E-08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PID2020-118127RB-I00; PID2021-127863OB-I00</GrantID><Agency>Ministerio de Ciencia, Innovación y Universidades</Agency><Country /></Grant><Grant><GrantID>2021SGR00357</GrantID><Agency>Agència de Gestió d'Ajuts Universitaris i de Recerca</Agency><Country /></Grant><Grant><GrantID>PRTR-C17.I1</GrantID><Agency>Ministerio de Ciencia, Innovación y Universidades</Agency><Country /></Grant><Grant><GrantID>300155</GrantID><Agency>Fundació Bosch i Gimpera</Agency><Country /></Grant><Grant><GrantID>ED431C 2022/20</GrantID><Agency>Xunta de Galicia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">BACE-1 inhibitors</Keyword><Keyword MajorTopicYN="N">DMPK properties</Keyword><Keyword MajorTopicYN="N">acetylcholinesterase inhibitors</Keyword><Keyword MajorTopicYN="N">butyrylcholinesterase inhibitors</Keyword><Keyword MajorTopicYN="N">multitarget drugs</Keyword><Keyword MajorTopicYN="N">tau anti-aggregating agents</Keyword><Keyword MajorTopicYN="N">zebrafish embryos</Keyword><Keyword MajorTopicYN="N">β-amyloid anti-aggregating agents</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39204327</ArticleId><ArticleId IdType="pmc">PMC11359831</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16080982</ArticleId><ArticleId IdType="pii">pharmaceutics16080982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morphy R., Rankovic Z. The Physicochemical Challenges of Designing Multiple Ligands. J. Med. Chem. 2006;49:4961–4970. doi: 10.1021/jm0603015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm0603015</ArticleId><ArticleId IdType="pubmed">16884308</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li X., Liu F., Li S., Shi D. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. J. Med. Chem. 2021;64:10581–10605. doi: 10.1021/acs.jmedchem.1c00683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00683</ArticleId><ArticleId IdType="pubmed">34313432</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Mahajan M., Kumar D., Singh K., Chowdhary M., Amit An Inclusive Study of Recent Advancements in Alzheimer’s Disease: A Comprehensive Review. Neuropeptides. 2023;102:102369. doi: 10.1016/j.npep.2023.102369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2023.102369</ArticleId><ArticleId IdType="pubmed">37611472</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessel J. The Several Ways to Authentically Cure Alzheimer’s Dementia. Ageing Res. Rev. 2023;92:102093. doi: 10.1016/j.arr.2023.102093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2023.102093</ArticleId><ArticleId IdType="pubmed">37865143</ArticleId></ArticleIdList></Reference><Reference><Citation>Joe E., Ringman J.M. Cognitive Symptoms of Alzheimer’s Disease: Clinical Management and Prevention. BMJ. 2019;367:l6217. doi: 10.1136/bmj.l6217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l6217</ArticleId><ArticleId IdType="pubmed">31810978</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccellato F.R., D’Anca M., Tartaglia G.M., Del Fabbro M., Scarpini E., Galimberti D. Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies. Int. J. Mol. Sci. 2023;24:13900. doi: 10.3390/ijms241813900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241813900</ArticleId><ArticleId IdType="pmc">PMC10531090</ArticleId><ArticleId IdType="pubmed">37762203</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S., Aisen P.S., Barkhof F., Chalkias S., Chen T., Cohen S., Dent G., Hansson O., Harrison K., Von Hehn C., et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J. Prev. Alzheimer’s Dis. 2022;9:197–210. doi: 10.14283/jpad.2022.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2022.30</ArticleId><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dyck C.H., Swanson C.J., Aisen P., Bateman R.J., Chen C., Gee M., Kanekiyo M., Li D., Reyderman L., Cohen S., et al. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med. 2023;388:9–21. doi: 10.1056/NEJMoa2212948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2212948</ArticleId><ArticleId IdType="pubmed">36449413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Aducanumab: European Agency Rejects Alzheimer’s Drug over Efficacy and Safety Concerns. BMJ. 2021;375:n3127. doi: 10.1136/bmj.n3127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n3127</ArticleId><ArticleId IdType="pubmed">34930757</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer’s Research UK  Development and Sale of Alzheimer’s Drug Aducanumab, Ceased.  [(accessed on 6 March 2024)].  Available online:  https://www.alzheimersresearchuk.org/news/development-and-sale-of-alzheimers-drug-aducanumab-ceased/</Citation></Reference><Reference><Citation>Kaur U., Reddy J., Tiwari A., Chakrabarti S., Chakrabarti S.S. Lecanemab: More Questions Than Answers! Clin. Drug Investig. 2024;44:1–10. doi: 10.1007/s40261-023-01331-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-023-01331-1</ArticleId><ArticleId IdType="pubmed">38095822</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer’s Research UK  New Alzheimer’s Treatment, Lecanemab, Makes the Headlines: What’s Next?  [(accessed on 6 March 2024)].  Available online:  https://www.alzheimersresearchuk.org/news/new-alzheimers-treatment-lecanemab-makes-the-headlines-whats-next/</Citation></Reference><Reference><Citation>Reardon S. FDA Approves Alzheimer’s Drug Lecanemab amid Safety Concerns. Nature. 2023;613:227–228. doi: 10.1038/d41586-023-00030-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-00030-3</ArticleId><ArticleId IdType="pubmed">36627422</ArticleId></ArticleIdList></Reference><Reference><Citation>Jönsson L., Wimo A., Handels R., Johansson G., Boada M., Engelborghs S., Frölich L., Jessen F., Kehoe P.G., Kramberger M., et al. The Affordability of Lecanemab, an Amyloid-Targeting Therapy for Alzheimer’s Disease: An EADC-EC Viewpoint. Lancet Reg. Health–Eur. 2023;29:100657. doi: 10.1016/j.lanepe.2023.100657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100657</ArticleId><ArticleId IdType="pmc">PMC10220264</ArticleId><ArticleId IdType="pubmed">37251789</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B., Amouyel P., Andrieu S., Ballard C., Brayne C., Brodaty H., Cedazo-Minguez A., Dubois B., Edvardsson D., Feldman H., et al. Defeating Alzheimer’s Disease and Other Dementias: A Priority for European Science and Society. Lancet Neurol. 2016;15:455–532. doi: 10.1016/S1474-4422(16)00062-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00062-4</ArticleId><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Flier W.M., De Vugt M.E., Smets E.M.A., Blom M., Teunissen C.E. Towards a Future Where Alzheimer’s Disease Pathology Is Stopped before the Onset of Dementia. Nat. Aging. 2023;3:494–505. doi: 10.1038/s43587-023-00404-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-023-00404-2</ArticleId><ArticleId IdType="pubmed">37202515</ArticleId></ArticleIdList></Reference><Reference><Citation>Viayna E., Sola I., Di Pietro O., Muñoz-Torrero D. Human Disease and Drug Pharmacology, Complex as Real Life. Curr. Med. Chem. 2013;20:1623–1634. doi: 10.2174/0929867311320130002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867311320130002</ArticleId><ArticleId IdType="pubmed">23410162</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H.M., Nisenbaum L.K., Burstein A.H. Future of Alzheimer’s Disease Treatment: Combination Therapy and Precision Medicine. J. Prev. Alzheimer’s Dis. 2023;4:743–745. doi: 10.14283/jpad.2023.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2023.112</ArticleId><ArticleId IdType="pubmed">37874094</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi M.L. Harnessing Polypharmacology with Medicinal Chemistry. ACS Med. Chem. Lett. 2019;10:273–275. doi: 10.1021/acsmedchemlett.9b00039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.9b00039</ArticleId><ArticleId IdType="pmc">PMC6421528</ArticleId><ArticleId IdType="pubmed">30891125</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertini C., Salerno A., De Sena Murteira Pinheiro P., Bolognesi M.L. From Combinations to Multitarget-directed Ligands: A Continuum in Alzheimer’s Disease Polypharmacology. Med. Res. Rev. 2021;41:2606–2633. doi: 10.1002/med.21699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21699</ArticleId><ArticleId IdType="pubmed">32557696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases. J. Med. Chem. 2008;51:347–372. doi: 10.1021/jm7009364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm7009364</ArticleId><ArticleId IdType="pubmed">18181565</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak C., Kabra U.D. A Comprehensive Review of Multi-Target Directed Ligands in the Treatment of Alzheimer’s Disease. Bioorganic Chem. 2024;144:107152. doi: 10.1016/j.bioorg.2024.107152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2024.107152</ArticleId><ArticleId IdType="pubmed">38290187</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiselin T., Lecoutey C., Rochais C., Dallemagne P. Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease. Pharmaceutics. 2023;15:2382. doi: 10.3390/pharmaceutics15102382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15102382</ArticleId><ArticleId IdType="pmc">PMC10610275</ArticleId><ArticleId IdType="pubmed">37896142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismaili L., Monnin J., Etievant A., Arribas R.L., Viejo L., Refouvelet B., Soukup O., Janockova J., Hepnarova V., Korabecny J., et al. (±)-BIGI-3h: Pentatarget-Directed Ligand Combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer’s Disease. ACS Chem. Neurosci. 2021;12:1328–1342. doi: 10.1021/acschemneuro.0c00803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00803</ArticleId><ArticleId IdType="pubmed">33797877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente-Zurdo D., Brunetti L., Piemontese L., Guedes B., Cardoso S.M., Chavarria D., Borges F., Madrid Y., Chaves S., Santos M.A. Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases. Int. J. Mol. Sci. 2023;24:8312. doi: 10.3390/ijms24098312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24098312</ArticleId><ArticleId IdType="pmc">PMC10179505</ArticleId><ArticleId IdType="pubmed">37176018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Kumar V., Anand P., Kumar V., Ranjan Dwivedi A., Kumar V. Advancements in the Development of Multi-Target Directed Ligands for the Treatment of Alzheimer’s Disease. Bioorg. Med. Chem. 2022;61:116742. doi: 10.1016/j.bmc.2022.116742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2022.116742</ArticleId><ArticleId IdType="pubmed">35398739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B., Vivesh, Singh P. Alzheimer’s Disease: Treatment of Multi-Factorial Disorders with Multi- Target Approach. Mini Rev. Med. Chem. 2023;23:380–398. doi: 10.2174/1389557522666220701112048.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557522666220701112048</ArticleId><ArticleId IdType="pubmed">35786334</ArticleId></ArticleIdList></Reference><Reference><Citation>Proschak E., Stark H., Merk D. Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds. J. Med. Chem. 2019;62:420–444. doi: 10.1021/acs.jmedchem.8b00760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00760</ArticleId><ArticleId IdType="pubmed">30035545</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampietro A., Pérez-Areales F.J., Martínez P., Arce E.M., Galdeano C., Muñoz-Torrero D. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals. 2022;15:545. doi: 10.3390/ph15050545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15050545</ArticleId><ArticleId IdType="pmc">PMC9146451</ArticleId><ArticleId IdType="pubmed">35631371</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M., Gazova Z., Von Bergen M., Khlistunova I., Wang Y., Hascher A., Mandelkow E.-M., Biernat J., Mandelkow E. Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer’s Paired Helical Filaments in Vitro and in Cells. J. Biol. Chem. 2005;280:3628–3635. doi: 10.1074/jbc.M410984200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M410984200</ArticleId><ArticleId IdType="pubmed">15525637</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B., Pickhardt M., Schmidt B., Mandelkow E., Waldmann H., Mandelkow E. Development of Tau Aggregation Inhibitors for Alzheimer’s Disease. Angew. Chem. Int. Ed. 2009;48:1740–1752. doi: 10.1002/anie.200802621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200802621</ArticleId><ArticleId IdType="pubmed">19189357</ArticleId></ArticleIdList></Reference><Reference><Citation>Camps P., El Achab R., Morral J., Muñoz-Torrero D., Badia A., Baños J.E., Vivas N.M., Barril X., Orozco M., Luque F.J. New Tacrine−Huperzine A Hybrids (Huprines): Highly Potent Tight-Binding Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer’s Disease. J. Med. Chem. 2000;43:4657–4666. doi: 10.1021/jm000980y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm000980y</ArticleId><ArticleId IdType="pubmed">11101357</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalá M.D.M., Vivas N.M., Hospital S., Camps P., Muñoz-Torrero D., Badia A. Characterisation of the Anticholinesterase Activity of Two New Tacrine–Huperzine A Hybrids. Neuropharmacology. 2003;44:749–755. doi: 10.1016/S0028-3908(03)00071-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(03)00071-6</ArticleId><ArticleId IdType="pubmed">12681373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Areales F.J., Betari N., Viayna A., Pont C., Espargaró A., Bartolini M., De Simone A., Rinaldi Alvarenga J.F., Pérez B., Sabate R., et al. Design, Synthesis and Multitarget Biological Profiling of Second-Generation Anti-Alzheimer Rhein–Huprine Hybrids. Future Med. Chem. 2017;9:965–981. doi: 10.4155/fmc-2017-0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2017-0049</ArticleId><ArticleId IdType="pubmed">28632395</ArticleId></ArticleIdList></Reference><Reference><Citation>Viayna E., Sola I., Bartolini M., De Simone A., Tapia-Rojas C., Serrano F.G., Sabaté R., Juárez-Jiménez J., Pérez B., Luque F.J., et al. Synthesis and Multitarget Biological Profiling of a Novel Family of Rhein Derivatives As Disease-Modifying Anti-Alzheimer Agents. J. Med. Chem. 2014;57:2549–2567. doi: 10.1021/jm401824w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm401824w</ArticleId><ArticleId IdType="pubmed">24568372</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pietro O., Juárez-Jiménez J., Muñoz-Torrero D., Laughton C.A., Luque F.J. Unveiling a Novel Transient Druggable Pocket in BACE-1 through Molecular Simulations: Conformational Analysis and Binding Mode of Multisite Inhibitors. PLoS ONE. 2017;12:e0177683. doi: 10.1371/journal.pone.0177683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177683</ArticleId><ArticleId IdType="pmc">PMC5432175</ArticleId><ArticleId IdType="pubmed">28505196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo G., Holtzman D.M. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease. In: Takashima A., Wolozin B., Buee L., editors. Tau Biology. Volume 1184. Springer; Singapore: 2019. pp. 187–203.</Citation></Reference><Reference><Citation>Luque F.J., Muñoz-Torrero D. Acetylcholinesterase: A Versatile Template to Coin Potent Modulators of Multiple Therapeutic Targets. Acc. Chem. Res. 2024;57:450–467. doi: 10.1021/acs.accounts.3c00617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.3c00617</ArticleId><ArticleId IdType="pmc">PMC10882973</ArticleId><ArticleId IdType="pubmed">38333993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochem. Pharmacol. 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(61)90145-9</ArticleId><ArticleId IdType="pubmed">13726518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehring K.A., Workman H.L., Miller K.D., Mandagere A., Poole S.K. Automated Robotic Liquid Handling/Laser-Based Nephelometry System for High Throughput Measurement of Kinetic Aqueous Solubility. J. Pharm. Biomed. Anal. 2004;36:447–456. doi: 10.1016/j.jpba.2004.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2004.07.022</ArticleId><ArticleId IdType="pubmed">15522517</ArticleId></ArticleIdList></Reference><Reference><Citation>Di L., Kerns E.H., Fan K., McConnell O.J., Carter G.T. High Throughput Artificial Membrane Permeability Assay for Blood–Brain Barrier. Eur. J. Med. Chem. 2003;38:223–232. doi: 10.1016/S0223-5234(03)00012-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0223-5234(03)00012-6</ArticleId><ArticleId IdType="pubmed">12667689</ArticleId></ArticleIdList></Reference><Reference><Citation>OECD . OECD Guidelines for the Testing of Chemicals, Section 2. OECD; Paris, France: 2013. Test No. 236: Fish Embryo Acute Toxicity (FET) Test.</Citation><ArticleIdList><ArticleId IdType="doi">10.1787/9789264203709-en</ArticleId></ArticleIdList></Reference><Reference><Citation>Barenys M., Molins A., Amorós-Galicia L., Flick B., Gómez-Catalán J. Implementation of a Functional Endpoint to the Zebrafish Embryotoxicity Test to Evaluate Craniofacial Abnormalities. Toxicol. In Vitro. 2019;61:104638. doi: 10.1016/j.tiv.2019.104638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tiv.2019.104638</ArticleId><ArticleId IdType="pubmed">31476374</ArticleId></ArticleIdList></Reference><Reference><Citation>ISO 7346-1:1996 [(accessed on 6 March 2024)];Water Quality—Determination of the Acute Lethal Toxicity of Substances to a Freshwater Fish [Brachydanio Rerio Hamilton-Buchanan (Teleostei, Cyprinidae)] 1996  Available online:  https://www.iso.org/standard/14026.html.</Citation></Reference><Reference><Citation>ISO 7346-2:1996 [(accessed on 6 March 2024)];Water Quality—Determination of the Acute Lethal Toxicity of Substances to a Freshwater Fish [Brachydanio Rerio Hamilton-Buchanan (Teleostei, Cyprinidae)] 1996  Available online:  https://www.iso.org/standard/14028.html.</Citation></Reference><Reference><Citation>Piovesana R., Salazar Intriago M.S., Dini L., Tata A.M. Cholinergic Modulation of Neuroinflammation: Focus on A7 Nicotinic Receptor. Int. J. Mol. Sci. 2021;22:4912. doi: 10.3390/ijms22094912.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094912</ArticleId><ArticleId IdType="pmc">PMC8125157</ArticleId><ArticleId IdType="pubmed">34066354</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., Wu Q., Mak S., Liu E.Y.L., Zheng B.Z.Y., Dong T.T.X., Pi R., Tsim K.W.K. Regulation of Acetylcholinesterase during the Lipopolysaccharide-induced Inflammatory Responses in Microglial Cells. FASEB J. 2022;36:e22189. doi: 10.1096/fj.202101302RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202101302RR</ArticleId><ArticleId IdType="pubmed">35129858</ArticleId></ArticleIdList></Reference><Reference><Citation>Llanes L.C., Kuehlewein I., França I.V.D., Da Silva L.V., Da Cruz Junior J.W. Anticholinesterase Agents For Alzheimer’s Disease Treatment: An Updated Overview. Curr. Med. Chem. 2023;30:701–724. doi: 10.2174/0929867329666220803113411.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867329666220803113411</ArticleId><ArticleId IdType="pubmed">35927804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimmyo Y., Kihara T., Akaike A., Niidome T., Sugimoto H. Flavonols and Flavones as BACE-1 Inhibitors: Structure–Activity Relationship in Cell-Free, Cell-Based and in Silico Studies Reveal Novel Pharmacophore Features. Biochim. Biophys. Acta. 2008;1780:819–825. doi: 10.1016/j.bbagen.2008.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2008.01.017</ArticleId><ArticleId IdType="pubmed">18295609</ArticleId></ArticleIdList></Reference><Reference><Citation>Espargaró A., Pont C., Gamez P., Muñoz-Torrero D., Sabate R. Amyloid Pan-Inhibitors: One Family of Compounds To Cope with All Conformational Diseases. ACS Chem. Neurosci. 2019;10:1311–1317. doi: 10.1021/acschemneuro.8b00398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00398</ArticleId><ArticleId IdType="pubmed">30380841</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig N.H., Utsuki T., Yu Q.-S., Zhu X., Holloway H.W., Perry T., Lee B., Ingram D.K., Lahiri D.K. A New Therapeutic Target in Alzheimer’s Disease Treatment: Attention to Butyrylcholinesterase. Curr. Med. Res. Opin. 2001;17:159–165. doi: 10.1185/03007990152673800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007990152673800</ArticleId><ArticleId IdType="pubmed">11900310</ArticleId></ArticleIdList></Reference><Reference><Citation>Darvesh S. Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer’s Disease. Curr. Alzheimer Res. 2016;13:1173–1177. doi: 10.2174/1567205013666160404120542.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666160404120542</ArticleId><ArticleId IdType="pubmed">27040140</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Bolaños J.G., López Ó. Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer’s Agents: An Updated Patent Review (2018-Present) Expert Opin. Ther. Pat. 2022;32:913–932. doi: 10.1080/13543776.2022.2083956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2022.2083956</ArticleId><ArticleId IdType="pubmed">35623095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha Z.Y., Mathew S., Yeong K.Y. Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool. Curr. Protein Pept. Sci. 2020;21:99–109. doi: 10.2174/1389203720666191107094949.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203720666191107094949</ArticleId><ArticleId IdType="pubmed">31702488</ArticleId></ArticleIdList></Reference><Reference><Citation>Du C., Wang L., Guan Q., Yang H., Chen T., Liu Y., Li Q., Lyu W., Lu X., Chen Y., et al. N-Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease. J. Med. Chem. 2022;65:11365–11387. doi: 10.1021/acs.jmedchem.2c00944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00944</ArticleId><ArticleId IdType="pubmed">35969197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Huang G. The Biological Activities of Butyrylcholinesterase Inhibitors. Biomed. Pharmacother. 2022;146:112556. doi: 10.1016/j.biopha.2021.112556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112556</ArticleId><ArticleId IdType="pubmed">34953393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Zhang H. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease. ACS Chem. Neurosci. 2019;10:852–862. doi: 10.1021/acschemneuro.8b00391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00391</ArticleId><ArticleId IdType="pubmed">30521323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pidany F., Kroustkova J., Jenco J., Breiterova K.H., Muckova L., Novakova L., Kunes J., Fibigar J., Kucera T., Novak M., et al. Carltonine-Derived Compounds for Targeted Butyrylcholinesterase Inhibition. RSC Med. Chem. 2024;15:1601–1625. doi: 10.1039/D4MD00060A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D4MD00060A</ArticleId><ArticleId IdType="pmc">PMC11110763</ArticleId><ArticleId IdType="pubmed">38784455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregor V.E., Emmerling M.R., Lee C., Moore C.J. The Synthesis and in Vitro Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activity of Tacrine (Cognex®) Derivaties. Bioorg. Med. Chem. Lett. 1992;2:861–864. doi: 10.1016/S0960-894X(00)80545-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-894X(00)80545-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodek S.T., Antosiewicz J., McCammon J.A., Straatsma T.P., Gilson M.K., Briggs J.M., Humblet C., Sussman J.L. Binding of Tacrine and 6-chlorotacrine by Acetylcholinesterase. Biopolymers. 1996;38:109–117. doi: 10.1002/(SICI)1097-0282(199601)38:1&lt;109::AID-BIP9&gt;3.0.CO;2-#.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0282(199601)38:1&lt;109::AID-BIP9&gt;3.0.CO;2-#</ArticleId><ArticleId IdType="pubmed">8679940</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M.A., Wegmann S., Dujardin S., Commins C., Schiantarelli J., Klickstein N., Kamath T.V., Carlson G.A., Nelken I., Hyman B.T. Tau Impairs Neural Circuits, Dominating Amyloid-β Effects, in Alzheimer Models in Vivo. Nat. Neurosci. 2019;22:57–64. doi: 10.1038/s41593-018-0289-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0289-8</ArticleId><ArticleId IdType="pmc">PMC6560629</ArticleId><ArticleId IdType="pubmed">30559471</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet R.M., Götz J. Amyloid-β and Tau in Alzheimer’s Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies. J. Alzheimers Dis. 2018;64:S517–S527. doi: 10.3233/JAD-179907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179907</ArticleId><ArticleId IdType="pubmed">29562514</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Wei Q., Liu F.-F., Hu F., Xie A., Zhu L.-Q., Liu D. Synaptic Dysfunction in Alzheimer’s Disease: Aβ, Tau, and Epigenetic Alterations. Mol. Neurobiol. 2018;55:3021–3032. doi: 10.1007/s12035-017-0533-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0533-3</ArticleId><ArticleId IdType="pubmed">28456942</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., De Strooper B., Kivipelto M., Holstege H., Chételat G., Teunissen C.E., Cummings J., Van Der Flier W.M. Alzheimer’s Disease. Lancet. 2021;397:1577–1590. doi: 10.1016/S0140-6736(20)32205-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Hong F., Yang S. Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022;27:1210. doi: 10.3390/molecules27041210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27041210</ArticleId><ArticleId IdType="pmc">PMC8876037</ArticleId><ArticleId IdType="pubmed">35209007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Vassar R., De Strooper B., Hardy J., Willem M., Singh N., Zhou J., Yan R., Vanmechelen E., De Vos A., et al. The β-Secretase BACE1 in Alzheimer’s Disease. Biol. Psychiatry. 2021;89:745–756. doi: 10.1016/j.biopsych.2020.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2020.02.001</ArticleId><ArticleId IdType="pmc">PMC7533042</ArticleId><ArticleId IdType="pubmed">32223911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chagas Monteiro K.L., Dos Santos Alcântara M.G., Lins Freire N.M., Brandão E.M., Do Nascimento V.L., Dos Santos Viana L.M., De Aquino T.M., Da Silva-Júnior E.F. BACE-1 Inhibitors Targeting Alzheimer’s Disease. Curr. Alzheimer Res. 2023;20:131–148. doi: 10.2174/1567205020666230612155953.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205020666230612155953</ArticleId><ArticleId IdType="pubmed">37309767</ArticleId></ArticleIdList></Reference><Reference><Citation>Espargaró A., Medina A., Di Pietro O., Muñoz-Torrero D., Sabate R. Ultra Rapid in Vivo Screening for Anti-Alzheimer Anti-Amyloid Drugs. Sci. Rep. 2016;6:23349. doi: 10.1038/srep23349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23349</ArticleId><ArticleId IdType="pmc">PMC4802339</ArticleId><ArticleId IdType="pubmed">27000658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerns E.H., Di L. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization. Academic Press; Amsterdam, The Netherlands: Boston, MA, USA: 2008. pp. 276–286.</Citation></Reference><Reference><Citation>Bevan C.D., Lloyd R.S. A High-Throughput Screening Method for the Determination of Aqueous Drug Solubility Using Laser Nephelometry in Microtiter Plates. Anal. Chem. 2000;72:1781–1787. doi: 10.1021/ac9912247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac9912247</ArticleId><ArticleId IdType="pubmed">10784141</ArticleId></ArticleIdList></Reference><Reference><Citation>MacRae C.A., Peterson R.T. Zebrafish as Tools for Drug Discovery. Nat. Rev. Drug Discov. 2015;14:721–731. doi: 10.1038/nrd4627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4627</ArticleId><ArticleId IdType="pubmed">26361349</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia G.R., Noyes P.D., Tanguay R.L. Advancements in Zebrafish Applications for 21st Century Toxicology. Pharmacol. Ther. 2016;161:11–21. doi: 10.1016/j.pharmthera.2016.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2016.03.009</ArticleId><ArticleId IdType="pmc">PMC4851906</ArticleId><ArticleId IdType="pubmed">27016469</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>